Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE TOMAS CASO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457308157
CMS profile
201338
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$11.57

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $11.57 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $11.57 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE TOMAS CASO

NPI 1457308157 · CMS profile ID 201338

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.5709/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738478165 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $11.57 1
PY2022 $1,200.00 1
PY2023 $4,459.41 20
PY2024 $1,274.65 11
PY2025 $35.85 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,513,175.40 309
PY2024 Recipient $2,105.91 13
PY2024 Principal investigator $5,484,672.89 220
PY2023 Recipient $1,815.05 10
PY2023 Principal investigator $6,619,562.71 1,445
PY2022 Principal investigator $4,761,350.73 1,335
PY2021 Principal investigator $244,385.00 24
PY2019 Principal investigator $19,780.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

309 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,523.94 12/24/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125396
Principal investigator 1 SANOFI US SERVICES INC. $1,523.94 12/24/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125416
Principal investigator 1 ModernaTX, Inc. $25,990.90 12/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968985
Principal investigator 1 ModernaTX, Inc. $4,567.68 12/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969011
Principal investigator 1 ModernaTX, Inc. $819.59 12/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969119
Principal investigator 1 SANOFI PASTEUR INC. $2,600.00 12/18/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226106052
Principal investigator 1 Janssen Research & Development, LLC $1,563.00 12/12/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196931
Principal investigator 1 SANOFI US SERVICES INC. $3,552.12 12/05/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125411
Principal investigator 1 ModernaTX, Inc. $200.20 12/04/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969005
Principal investigator 1 ModernaTX, Inc. $468.00 12/04/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969173
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 12/03/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125407
Principal investigator 1 SANOFI PASTEUR INC. $500.00 12/02/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226106038
Principal investigator 1 SANOFI PASTEUR INC. $4,000.00 12/02/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226106044
Principal investigator 1 ModernaTX, Inc. $652.06 12/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969043
Principal investigator 1 ModernaTX, Inc. $6,997.55 11/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968993
Principal investigator 1 ModernaTX, Inc. $1,629.25 11/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968997
Principal investigator 1 ModernaTX, Inc. $5,035.68 11/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969099
Principal investigator 1 ModernaTX, Inc. $1,639.18 11/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969115
Principal investigator 1 ModernaTX, Inc. $1,964.78 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968961
Principal investigator 1 ModernaTX, Inc. $7,593.60 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968965
Principal investigator 1 ModernaTX, Inc. $8,038.80 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968967
Principal investigator 1 ModernaTX, Inc. $2,522.16 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968971
Principal investigator 1 ModernaTX, Inc. $13.17 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969027
Principal investigator 1 ModernaTX, Inc. $8,916.18 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969075
Principal investigator 1 ModernaTX, Inc. $489.85 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969077
Principal investigator 1 ModernaTX, Inc. $3,758.70 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969081
Principal investigator 1 ModernaTX, Inc. $3,879.68 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969085
Principal investigator 1 ModernaTX, Inc. $1,236.62 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969089
Principal investigator 1 ModernaTX, Inc. $2,887.20 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969131
Principal investigator 1 ModernaTX, Inc. $3,620.48 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969133
Principal investigator 1 ModernaTX, Inc. $64.06 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969135
Principal investigator 1 ModernaTX, Inc. $3,388.44 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969137
Principal investigator 1 ModernaTX, Inc. $150.66 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969139
Principal investigator 1 ModernaTX, Inc. $157.42 11/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969141
Principal investigator 1 Bavarian Nordic A/S $1,535.58 11/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215148
Principal investigator 1 ModernaTX, Inc. $2,500.00 11/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968963
Principal investigator 1 ModernaTX, Inc. $3,000.00 11/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969083
Principal investigator 1 ModernaTX, Inc. $4,000.00 11/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969091
Principal investigator 1 Boehringer Ingelheim International GmbH $132.00 11/20/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769589
Principal investigator 1 Boehringer Ingelheim International GmbH $76.00 11/20/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769591
Principal investigator 1 SANOFI US SERVICES INC. $1,523.94 11/20/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125404
Principal investigator 1 SANOFI PASTEUR INC. $49,284.88 11/17/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226100063
Principal investigator 1 SANOFI PASTEUR INC. $24,883.19 11/14/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105967
Principal investigator 1 Bavarian Nordic A/S $8,038.21 11/12/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215302
Principal investigator 1 SANOFI PASTEUR INC. $2,256.30 11/12/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100051
Principal investigator 1 SANOFI PASTEUR INC. $300.00 11/12/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100057
Principal investigator 1 SANOFI US SERVICES INC. $351.00 11/12/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125400
Principal investigator 1 Boehringer Ingelheim International GmbH $1,575.00 11/10/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769593
Principal investigator 1 Janssen Research & Development, LLC $726.00 11/07/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196178
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/05/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969113
Principal investigator 1 Janssen Research & Development, LLC $1,584.00 11/03/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196110
Principal investigator 1 ModernaTX, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969127
Principal investigator 1 ModernaTX, Inc. $200.20 10/29/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969159
Principal investigator 1 SANOFI PASTEUR INC. $400.00 10/29/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226100089
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 10/29/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100096
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 10/29/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100103
Principal investigator 1 SANOFI PASTEUR INC. $750.00 10/29/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226106023
Principal investigator 1 SANOFI PASTEUR INC. $4,540.00 10/29/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226106034
Principal investigator 1 Boehringer Ingelheim International GmbH $450.00 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769577
Principal investigator 1 Boehringer Ingelheim International GmbH $2,107.50 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769581
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769595
Principal investigator 1 ModernaTX, Inc. $400.00 10/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968983
Principal investigator 1 ModernaTX, Inc. $9,449.65 10/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969001
Principal investigator 1 ModernaTX, Inc. $348.40 10/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969071
Principal investigator 1 ModernaTX, Inc. $4,661.28 10/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969121
Principal investigator 1 ModernaTX, Inc. $260.00 10/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969125
Principal investigator 1 SANOFI PASTEUR INC. $450.00 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100078
Principal investigator 1 SANOFI PASTEUR INC. $1,504.20 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100084
Principal investigator 1 SANOFI PASTEUR INC. $650.00 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105988
Principal investigator 1 SANOFI PASTEUR INC. $2,632.35 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105995
Principal investigator 1 SANOFI PASTEUR INC. $3,384.45 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105999
Principal investigator 1 SANOFI PASTEUR INC. $200.00 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226106004
Principal investigator 1 SANOFI PASTEUR INC. $3,384.45 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226106011
Principal investigator 1 SANOFI PASTEUR INC. $1,128.15 10/27/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226106015
Principal investigator 1 SANOFI PASTEUR INC. $30,810.28 10/23/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226100073
Principal investigator 1 Bavarian Nordic A/S $1,295.00 10/22/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215308
Principal investigator 1 SANOFI PASTEUR INC. $350.00 10/22/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100068
Principal investigator 1 SANOFI PASTEUR INC. $4,888.65 10/22/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105976
Principal investigator 1 SANOFI PASTEUR INC. $150.00 10/22/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105982
Principal investigator 1 SANOFI PASTEUR INC. $18,346.50 10/17/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105972
Principal investigator 1 ModernaTX, Inc. $2,300.00 10/16/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969007
Principal investigator 1 ModernaTX, Inc. $950.95 10/16/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005683
Principal investigator 1 SANOFI PASTEUR INC. $79,698.97 10/10/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226100047
Principal investigator 1 ModernaTX, Inc. $10,766.08 10/08/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969105
Principal investigator 1 Bavarian Nordic A/S $12,772.13 10/03/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215304
Principal investigator 1 Bavarian Nordic A/S $300.00 10/03/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215306
Principal investigator 1 Boehringer Ingelheim International GmbH $1,642.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769567
Principal investigator 1 Boehringer Ingelheim International GmbH $2,043.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769569
Principal investigator 1 Boehringer Ingelheim International GmbH $2,145.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769571
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769573
Principal investigator 1 Boehringer Ingelheim International GmbH $12,500.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769575
Principal investigator 1 Boehringer Ingelheim International GmbH $2,945.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769579
Principal investigator 1 Boehringer Ingelheim International GmbH $950.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769583
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769585
Principal investigator 1 Boehringer Ingelheim International GmbH $2,760.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769587
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 10/02/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226100041
Principal investigator 1 Bavarian Nordic A/S $2,844.53 10/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215300
Principal investigator 1 ModernaTX, Inc. $4,305.60 09/29/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968999
Principal investigator 1 ModernaTX, Inc. $8,472.10 09/29/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969061
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 09/24/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769561
Principal investigator 1 Boehringer Ingelheim International GmbH $519.48 09/24/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769563
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 09/24/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769565
Principal investigator 1 Bavarian Nordic A/S $822.00 09/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215298
Principal investigator 1 Janssen Research & Development, LLC $5,012.00 09/19/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175194103
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968969
Principal investigator 1 ModernaTX, Inc. $600.00 09/17/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969055
Principal investigator 1 Janssen Research & Development, LLC $855.00 09/12/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175194275
Principal investigator 1 Bavarian Nordic A/S $575.40 09/10/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215296
Principal investigator 1 Bavarian Nordic A/S $2,400.00 09/01/2025 Non-covered Recipient Entity
Suncoast Research Associates
EBSI-CV-317-005 No dispute reported 06/30/2026 1250214288
Principal investigator 1 ModernaTX, Inc. $1,955.10 08/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968995
Principal investigator 1 ModernaTX, Inc. $4,848.48 08/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969035
Principal investigator 1 ModernaTX, Inc. $9,344.34 08/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969045
Principal investigator 1 ModernaTX, Inc. $819.59 08/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969057
Principal investigator 1 ModernaTX, Inc. $335.92 08/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005677
Principal investigator 1 ModernaTX, Inc. $837.32 08/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005679
Principal investigator 1 Bavarian Nordic A/S $8,022.95 08/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215290
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 08/27/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769559
Principal investigator 1 Janssen Research & Development, LLC $2,155.00 08/13/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175195616
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,700.00 08/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185544477
Principal investigator 1 Bavarian Nordic A/S $2,744.00 08/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215288
Principal investigator 1 Bavarian Nordic A/S $9,828.34 08/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215292
Principal investigator 1 Bavarian Nordic A/S $13,307.69 08/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215294
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 07/31/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769557
Principal investigator 1 ModernaTX, Inc. $326.03 07/31/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969053
Principal investigator 1 ModernaTX, Inc. $500.00 07/31/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969063
Principal investigator 1 ModernaTX, Inc. $1,038.26 07/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969003
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969025
Principal investigator 1 ModernaTX, Inc. $1,216.80 07/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969109
Principal investigator 1 Janssen Research & Development, LLC $1,253.00 07/23/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175194197
Principal investigator 1 ModernaTX, Inc. $303.75 07/16/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969017
Principal investigator 1 ModernaTX, Inc. $500.00 07/16/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969019
Principal investigator 1 ModernaTX, Inc. $792.00 07/09/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005637
Principal investigator 1 ModernaTX, Inc. $500.00 07/09/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005649
Principal investigator 1 ModernaTX, Inc. $3,837.60 06/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969037
Principal investigator 1 ModernaTX, Inc. $4,236.05 06/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969039
Principal investigator 1 ModernaTX, Inc. $24,918.24 06/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969161
Principal investigator 1 Janssen Research & Development, LLC $2,080.00 06/26/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175195418
Principal investigator 1 Bavarian Nordic A/S $746.32 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215280
Principal investigator 1 ModernaTX, Inc. $6,000.00 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968991
Principal investigator 1 ModernaTX, Inc. $746.20 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969009
Principal investigator 1 ModernaTX, Inc. $4,085.00 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969097
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969101
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969111
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969149
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/25/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005685
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769551
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 06/24/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769553
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220769555
Principal investigator 1 SANOFI PASTEUR INC. $858.60 06/24/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105960
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 06/24/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125392
Principal investigator 1 Bavarian Nordic A/S $812.51 06/20/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215278
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 06/20/2025 Non-covered Recipient Entity
Suncoast Research Associates LLC Pembroke Pines
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220998405
Principal investigator 1 Janssen Research & Development, LLC $2,904.00 06/20/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196368
Principal investigator 1 SANOFI US SERVICES INC. $5,328.18 06/20/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125389
Principal investigator 1 ModernaTX, Inc. $28,033.02 06/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969051
Principal investigator 1 ModernaTX, Inc. $819.59 06/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969059
Principal investigator 1 ModernaTX, Inc. $11,404.75 06/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969123
Principal investigator 1 ModernaTX, Inc. $4,118.40 06/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969175
Principal investigator 1 ModernaTX, Inc. $41,447.34 06/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005643
Principal investigator 1 SANOFI PASTEUR INC. $388,149.36 06/17/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105954
Principal investigator 1 ModernaTX, Inc. $20.70 06/13/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969201
Principal investigator 1 ModernaTX, Inc. $496.80 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969177
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969179
Principal investigator 1 ModernaTX, Inc. $82.80 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969181
Principal investigator 1 ModernaTX, Inc. $156.01 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969183
Principal investigator 1 ModernaTX, Inc. $89,317.84 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969185
Principal investigator 1 ModernaTX, Inc. $5,871.65 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969187
Principal investigator 1 ModernaTX, Inc. $379.50 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969189
Principal investigator 1 ModernaTX, Inc. $950.00 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969193
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969195
Principal investigator 1 ModernaTX, Inc. $200.58 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969197
Principal investigator 1 ModernaTX, Inc. $500.00 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969203
Principal investigator 1 ModernaTX, Inc. $3,520.80 06/11/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969207
Principal investigator 1 SANOFI PASTEUR INC. $2,200.50 06/11/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105948
Principal investigator 1 SANOFI PASTEUR INC. $50,190.94 06/10/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105936
Principal investigator 1 SANOFI PASTEUR INC. $72,059.50 06/10/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105943
Principal investigator 1 Janssen Research & Development, LLC $792.00 06/09/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175195787
Principal investigator 1 SANOFI PASTEUR INC. $4,969.40 06/09/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105912
Principal investigator 1 SANOFI PASTEUR INC. $15,405.14 06/09/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105919
Principal investigator 1 SANOFI PASTEUR INC. $19,877.60 06/09/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105924
Principal investigator 1 SANOFI PASTEUR INC. $27,828.64 06/09/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105930
Principal investigator 1 ModernaTX, Inc. $1,980.00 06/06/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969199
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/04/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968973
Principal investigator 1 ModernaTX, Inc. $250.08 06/04/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968977
Principal investigator 1 SANOFI PASTEUR INC. $2,800.00 06/02/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105889
Principal investigator 1 SANOFI US SERVICES INC. $500.00 06/02/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125385
Principal investigator 1 ModernaTX, Inc. $4,455.36 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968987
Principal investigator 1 ModernaTX, Inc. $6,229.56 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969033
Principal investigator 1 ModernaTX, Inc. $819.59 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969117
Principal investigator 1 ModernaTX, Inc. $20,202.70 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969151
Principal investigator 1 ModernaTX, Inc. $81,220.04 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005633
Principal investigator 1 ModernaTX, Inc. $4,258.89 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005653
Principal investigator 1 ModernaTX, Inc. $25,984.40 05/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005667
Principal investigator 1 Bavarian Nordic A/S $1,822.10 05/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215286
Principal investigator 1 SANOFI PASTEUR INC. $237,593.70 05/07/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105810
Principal investigator 1 SANOFI PASTEUR INC. $450.00 05/02/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105804
Principal investigator 1 ModernaTX, Inc. $1,639.18 04/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969103
Principal investigator 1 ModernaTX, Inc. $23,135.35 04/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969155
Principal investigator 1 ModernaTX, Inc. $4,380.48 04/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969157
Principal investigator 1 ModernaTX, Inc. $33,117.76 04/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005629
Principal investigator 1 ModernaTX, Inc. $19,677.02 04/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005647
Principal investigator 1 ModernaTX, Inc. $14,196.30 04/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005659
Principal investigator 1 SANOFI PASTEUR INC. $19,351.02 04/28/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105821
Principal investigator 1 SANOFI PASTEUR INC. $4,649.48 04/28/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105826
Principal investigator 1 Janssen Research & Development, LLC $3,232.00 04/23/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175194441
Principal investigator 1 SANOFI PASTEUR INC. $1,239.30 04/21/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105815
Principal investigator 1 Bavarian Nordic A/S $17,087.32 04/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215276
Principal investigator 1 Bavarian Nordic A/S $2,250.00 04/18/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215284
Principal investigator 1 ModernaTX, Inc. $500.00 04/07/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969169
Principal investigator 1 Bavarian Nordic A/S $1,109.70 04/02/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215282
Principal investigator 1 Bavarian Nordic A/S $16,723.92 04/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215274
Principal investigator 1 ModernaTX, Inc. $221.00 04/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005657
Principal investigator 1 ModernaTX, Inc. $264.00 04/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005661
Principal investigator 1 ModernaTX, Inc. $14,807.00 03/28/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005651
Principal investigator 1 SANOFI US SERVICES INC. $32,468.80 03/28/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125421
Principal investigator 1 SANOFI US SERVICES INC. $7,183.59 03/28/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125448
Principal investigator 1 SANOFI PASTEUR INC. $15,840.00 03/26/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226105873
Principal investigator 1 SANOFI PASTEUR INC. $5,178.60 03/26/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105878
Principal investigator 1 SANOFI PASTEUR INC. $166,499.76 03/26/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105883
Principal investigator 1 ModernaTX, Inc. $11,286.99 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969047
Principal investigator 1 ModernaTX, Inc. $14,989.10 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969065
Principal investigator 1 ModernaTX, Inc. $149.76 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969163
Principal investigator 1 ModernaTX, Inc. $4,455.36 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969167
Principal investigator 1 ModernaTX, Inc. $29,812.23 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005635
Principal investigator 1 ModernaTX, Inc. $30,904.64 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005639
Principal investigator 1 ModernaTX, Inc. $25,956.92 03/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005673
Principal investigator 1 Bavarian Nordic A/S $700.00 03/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215266
Principal investigator 1 Bavarian Nordic A/S $1,944.39 03/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215268
Principal investigator 1 Janssen Research & Development, LLC $2,506.00 03/21/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175195751
Principal investigator 1 SANOFI PASTEUR INC. $4,969.40 03/20/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105864
Principal investigator 1 SANOFI PASTEUR INC. $750.00 03/20/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105868
Principal investigator 1 SANOFI US SERVICES INC. $150,885.72 03/20/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226104417
Principal investigator 1 SANOFI US SERVICES INC. $690.00 03/20/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125437
Principal investigator 1 SANOFI US SERVICES INC. $1,073.24 03/20/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125440
Principal investigator 1 SANOFI PASTEUR INC. $14,200.00 03/19/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105850
Principal investigator 1 SANOFI PASTEUR INC. $600.00 03/19/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105857
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 03/19/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226104400
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 03/19/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125427
Principal investigator 1 Merck Sharp & Dohme LLC $31,674.00 03/17/2025 Non-covered Recipient Entity
Suncoast Research Associates
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older No dispute reported 06/30/2026 1232933874
Principal investigator 1 Bavarian Nordic A/S $400.00 03/14/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215272
Principal investigator 1 Janssen Research & Development, LLC $572.00 03/14/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196260
Principal investigator 1 SANOFI PASTEUR INC. $10,419.78 03/14/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1226105844
Principal investigator 1 SANOFI US SERVICES INC. $32,027.87 03/07/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125424
Principal investigator 1 Janssen Research & Development, LLC $1,495.00 03/03/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175197248
Principal investigator 1 SANOFI PASTEUR INC. $2,316.60 03/03/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105831
Principal investigator 1 SANOFI PASTEUR INC. $679,006.01 03/03/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105838
Principal investigator 1 ModernaTX, Inc. $40,130.09 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968989
Principal investigator 1 ModernaTX, Inc. $5,110.56 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969013
Principal investigator 1 ModernaTX, Inc. $26,678.34 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969049
Principal investigator 1 ModernaTX, Inc. $21,506.10 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969073
Principal investigator 1 ModernaTX, Inc. $4,417.92 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969095
Principal investigator 1 ModernaTX, Inc. $14,196.30 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005631
Principal investigator 1 ModernaTX, Inc. $34,856.64 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005645
Principal investigator 1 ModernaTX, Inc. $54,844.46 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005663
Principal investigator 1 ModernaTX, Inc. $11,615.24 02/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005665
Principal investigator 1 Bavarian Nordic A/S $5,152.28 02/26/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215246
Principal investigator 1 Bavarian Nordic A/S $6,812.93 02/26/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215260
Principal investigator 1 Bavarian Nordic A/S $270.84 02/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215252
Principal investigator 1 Bavarian Nordic A/S $1,200.00 02/21/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215270
Principal investigator 1 Janssen Research & Development, LLC $2,705.00 02/19/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196163
Principal investigator 1 ModernaTX, Inc. $243.00 02/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969015
Principal investigator 1 ModernaTX, Inc. $94.50 02/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969021
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969023
Principal investigator 1 ModernaTX, Inc. $67.50 02/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969143
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $156,764.72 02/19/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123758
Principal investigator 1 Bavarian Nordic A/S $2,603.00 02/14/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215248
Principal investigator 1 Bavarian Nordic A/S $812.51 02/14/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215254
Principal investigator 1 Bavarian Nordic A/S $14,199.53 02/14/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215256
Principal investigator 1 Bavarian Nordic A/S $270.84 02/12/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215250
Principal investigator 1 Bavarian Nordic A/S $260.30 02/12/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215258
Principal investigator 1 Bavarian Nordic A/S $700.00 02/07/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215262
Principal investigator 1 Bavarian Nordic A/S $609.55 02/07/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
EBSI-CV-317-008 No dispute reported 06/30/2026 1250215264
Principal investigator 1 SANOFI US SERVICES INC. $14,418.99 02/07/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226104413
Principal investigator 1 SANOFI US SERVICES INC. $179,344.80 02/03/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125432
Principal investigator 1 ModernaTX, Inc. $6,296.94 01/30/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968975
Principal investigator 1 ModernaTX, Inc. $8,720.00 01/29/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969205
Principal investigator 1 ModernaTX, Inc. $4,800.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252968979
Principal investigator 1 ModernaTX, Inc. $750.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252968981
Principal investigator 1 ModernaTX, Inc. $2,500.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252969029
Principal investigator 1 ModernaTX, Inc. $2,590.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252969031
Principal investigator 1 ModernaTX, Inc. $819.59 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969041
Principal investigator 1 ModernaTX, Inc. $8,146.25 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969067
Principal investigator 1 ModernaTX, Inc. $52,760.34 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969087
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252969093
Principal investigator 1 ModernaTX, Inc. $2,283.84 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969107
Principal investigator 1 ModernaTX, Inc. $5,000.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252969145
Principal investigator 1 ModernaTX, Inc. $1,000.00 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age No dispute reported 06/30/2026 1252969147
Principal investigator 1 ModernaTX, Inc. $4,455.36 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969153
Principal investigator 1 ModernaTX, Inc. $17,443.53 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969165
Principal investigator 1 ModernaTX, Inc. $92,607.90 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969171
Principal investigator 1 ModernaTX, Inc. $35,145.80 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005641
Principal investigator 1 ModernaTX, Inc. $24,047.92 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005655
Principal investigator 1 ModernaTX, Inc. $15,615.93 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005671
Principal investigator 1 ModernaTX, Inc. $12,559.80 01/27/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005681
Principal investigator 1 ModernaTX, Inc. $2,640.00 01/24/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968959
Principal investigator 1 SANOFI US SERVICES INC. $600.00 01/23/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226104419
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 01/23/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226125444
Principal investigator 1 Janssen Research & Development, LLC $1,195.00 01/22/2025 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175196954
Principal investigator 1 ModernaTX, Inc. $200.00 01/22/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252969191
Principal investigator 1 ModernaTX, Inc. $29,867.76 01/22/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005669
Principal investigator 1 ModernaTX, Inc. $68.30 01/20/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252969069
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,553.09 01/15/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP, LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185544475
Principal investigator 1 ModernaTX, Inc. $13,500.00 01/08/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969129
Principal investigator 1 ModernaTX, Inc. $8,177.00 01/08/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253005675
Principal investigator 1 SANOFI PASTEUR INC. $257,573.88 01/07/2025 Non-covered Recipient Entity
Suncoast Research Associates Llc
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1226105798
Principal investigator 1 ModernaTX, Inc. $6,750.00 01/06/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252969079
Principal investigator 1 SANOFI US SERVICES INC. $17,608.57 01/03/2025 Non-covered Recipient Entity
Suncoast Research Associates, Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1226104407
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $635,214.88 01/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124364
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $365,668.85 01/01/2025 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124946